Literature DB >> 31436367

Development of a Model to Predict Portal Vein Thrombosis in Liver Transplant Candidates: The Portal Vein Thrombosis Risk Index.

Daniel Gaballa1, Dmitri Bezinover2, Zakiyah Kadry3, Elaine Eyster4, Ming Wang5, Patrick G Northup6, Jonathan G Stine5,7.   

Abstract

Portal vein thrombosis (PVT) is associated with inferior pretransplantation and posttransplantation outcomes. We aimed to create a predictive model to risk stratify transplant candidates for PVT. Data on adult transplants in the United States during the Model for End-Stage Liver Disease (MELD) era through September 2016 were reviewed. We constructed and validated a scoring system composed of routine, readily available clinical information to predict the development of incident PVT at 12 months from transplantation listing. A total of 66,568 liver transplant candidates were dichotomized into 2 groups to construct (n = 34,751) and validate (n = 31,817) a scoring system. In general, the derivation and validation cohorts were clinically similar. Although nonalcoholic steatohepatitis was a significant predictor of incident PVT (hazard ratio, 1.29; 95% confidence interval, 1.08-1.54; P < 0.001), age, MELD score, and moderate-to-severe ascites were also associated with increased risk. African American race was associated with decreased risk. A scoring system (PVT risk index [RI]) of these 5 variables had an area under the curve of 0.71 and 0.70 in both derivation and validation cohorts, respectively. By applying the low cutoff score of 2.6, incident PVT could be accurately excluded (negative predictive value 94%). Using the high cutoff score of 4.6 (positive predictive value 85%), PVT could be diagnosed with high accuracy. The PVT-RI predicts which candidates awaiting lifesaving liver transplantation will and will not develop future PVT. Although this scoring system will require prospective validation, it provides a powerful new tool for the clinician when risk stratifying cirrhosis patients prior to liver transplantation for future PVT development.
Copyright © 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2019        PMID: 31436367      PMCID: PMC6864229          DOI: 10.1002/lt.25630

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  28 in total

1.  Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity.

Authors:  Ton Lisman; Tamara N Bongers; Jelle Adelmeijer; Harry L A Janssen; Moniek P M de Maat; Philip G de Groot; Frank W G Leebeek
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

2.  Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis.

Authors:  Jonathan G Stine; Neeral L Shah; Curtis K Argo; Shawn J Pelletier; Stephen H Caldwell; Patrick G Northup
Journal:  Liver Transpl       Date:  2015-07-01       Impact factor: 5.799

3.  Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States.

Authors:  Ashwani Kumar Singal; Mohsen Hasanin; Mohamed Kaif; Russell Wiesner; Yong-Fang Kuo
Journal:  Transplantation       Date:  2016-03       Impact factor: 4.939

4.  Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic Steatohepatitis.

Authors:  Uchenna Agbim; Yu Jiang; Satish K Kedia; Ashwani K Singal; Aijaz Ahmed; Kalyan Ram Bhamidimarri; David E Bernstein; Stephen A Harrison; Zobair M Younossi; Sanjaya K Satapathy
Journal:  Liver Transpl       Date:  2019-01       Impact factor: 5.799

5.  Toward a Comprehensive New Classification of Portal Vein Thrombosis in Patients With Cirrhosis.

Authors:  Shiv K Sarin; Cyriac A Philips; Patrick S Kamath; Ashok Choudhury; Hitoshi Maruyama; Filipe G Nery; Dominique C Valla
Journal:  Gastroenterology       Date:  2016-08-27       Impact factor: 22.682

6.  OPTN/SRTR 2017 Annual Data Report: Liver.

Authors:  W R Kim; J R Lake; J M Smith; D P Schladt; M A Skeans; S M Noreen; A M Robinson; E Miller; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2019-02       Impact factor: 8.086

7.  Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis.

Authors:  Bernd Saugel; Marcel Lee; Stephanie Feichtinger; Alexander Hapfelmeier; Roland M Schmid; Jens T Siveke
Journal:  J Thromb Thrombolysis       Date:  2015-07       Impact factor: 2.300

8.  African Americans have a lower prevalence of portal vein thrombosis at the time of liver transplantation.

Authors:  Dmitri Bezinover; Ethan Reeder; Faisal Aziz; Fuat Saner; Patrick McQuillan; Zakiyah Kadry; Thomas Riley; Dmitri Guvakov; Piotr K Janicki
Journal:  HPB (Oxford)       Date:  2017-05-08       Impact factor: 3.647

9.  Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference.

Authors:  N M Intagliata; C K Argo; J G Stine; T Lisman; S H Caldwell; F Violi
Journal:  Thromb Haemost       Date:  2018-07-30       Impact factor: 5.249

10.  Autoimmune conditions are associated with perioperative thrombotic complications in liver transplant recipients: A UNOS database analysis.

Authors:  Dmitri Bezinover; Khaled Iskandarani; Vernon Chinchilli; Patrick McQuillan; Fuat Saner; Zakiyah Kadry; Thomas R Riley; Piotr K Janicki
Journal:  BMC Anesthesiol       Date:  2016-05-21       Impact factor: 2.217

View more
  7 in total

1.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

Review 2.  Advances in stent therapy for malignant biliary obstruction.

Authors:  Xin He; Ying Zhu; Yining Wang; Yuanzhen Hao; Junbo Hong
Journal:  Abdom Radiol (NY)       Date:  2021-01

3.  Metabolic Disorders and Risk of Portal Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis.

Authors:  Jiao Li; Qiong Wang; Mei Yang; Xiaobin Sun
Journal:  Turk J Gastroenterol       Date:  2022-07       Impact factor: 1.555

4.  Liver Cirrhosis Patients Homozygous for MTHFR C677T Develop Portal Vein Thrombosis 8 Years Earlier Than Wild Type.

Authors:  Paul R J Ames; Giovanna D'Andrea; Alessia Arcaro; Vincenzo Marottoli; Luigi Iannaccone; Maurizio Maraglione; Fabrizio Gentile
Journal:  Dig Dis Sci       Date:  2022-08-24       Impact factor: 3.487

Review 5.  Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: What is the evidence?

Authors:  Marco Biolato; Mattia Paratore; Luca Di Gialleonardo; Giuseppe Marrone; Antonio Grieco
Journal:  World J Hepatol       Date:  2022-04-27

6.  Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.

Authors:  Ellen G Driever; Fien A von Meijenfeldt; Jelle Adelmeijer; Robbert J de Haas; Marius C van den Heuvel; Chandrasekaran Nagasami; John W Weisel; Constantino Fondevila; Robert J Porte; Anabel Blasi; Nigel Heaton; Stephen Gregory; Pauline Kane; William Bernal; Yoh Zen; Ton Lisman
Journal:  Hepatology       Date:  2021-12-05       Impact factor: 17.298

7.  Portal vein thrombosis risk factors in liver transplant candidates.

Authors:  Cagatay Ak; Gupse Adali; Suleyman Sayar; Abdulbaki Agackiran; Fatma Kulali; Resul Kahraman; Oguzhan Ozturk; Kamil Ozdil
Journal:  Hepatol Forum       Date:  2022-09-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.